Tata Elxsi at DeviceTalks Boston 2026
Booth 806 | 27th & 28th May 2026 | Meet Us @ Boston Convention and Exhibition Center
Where Engineering Innovation Meets Intelligent Automation and Assured Compliance
Tata Elxsi is excited to be exhibiting at the DeviceTalks Boston 2026!
Join us at Booth 806 as we showcase how medical device organizations are accelerating innovation, strengthening regulatory readiness, optimizing operations, and enabling connected, AI-driven healthcare solutions.
At the event, Tata Elxsi will present focused demonstrations and solution showcases across four key areas shaping the future of MedTech:
Assured Compliance
Explore how AI, automation, and material intelligence are enabling audit-ready compliance, traceable workflows, and faster regulatory readiness across the medical device lifecycle.
Engineering Innovation
Discover how advanced engineering, AI-driven development, and integrated product design are accelerating innovation from concept to validation and deployment.
Manufacturing & Deployment
See how connected operations, predictive maintenance, and real-time monitoring are improving manufacturing efficiency, operational visibility, and field service execution.
Intelligent Devices & Robotics
Experience how embedded intelligence, connected systems, AI-enabled diagnostics, and robotics are shaping the next generation of healthcare solutions.
Visit us at Booth 806 to explore how engineering, automation, and compliance-driven innovation are enabling scalable, real-world healthcare impact.
Tata Elxsi Speaker Session
AI‑Native Digital Thread for MedTech: From Code Traceability to Material DNA
A regulatory crisis exposed a core challenge: compliance can’t rely on black‑box automation without weakening the expertise regulators demand. This session introduces ThELix OS, where autonomous agents streamline workflows while domain experts stay in control. Through ViTel™ and AnaTel™, it unifies material and supplier intelligence into a Material DNA layer and accelerates regulated software with faster submissions, traceability, and clinical evidence intelligence.
Attendees will see how this approach delivers real impact—70% less regulatory research effort, 60% reduced clinical review workload, and SaMD change assessments in 72 hours vs. eight weeks—turning compliance into a true competitive advantage.
